SCHEDULE: RA Capital Boosts Stake in Bicara Therapeutics

RA Capital Management and its affiliates increased their beneficial ownership in Bicara Therapeutics Inc. to 11.5% following a $40 million investment in a public offering.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, and Rajeev Shah, along with RA Capital Healthcare Fund, L.P., collectively increased their beneficial ownership in Bicara Therapeutics Inc.
• The group now beneficially owns 7,279,739 shares of common stock, representing 11.5% of the company's outstanding shares.
• This includes 4,603,418 shares held by RA Capital Healthcare Fund, L.P. (7.3% of class), 2,652,575 shares by RA Capital Nexus Fund III, L.P., and 23,746 shares underlying vested stock options.
• On February 26, 2026, RA Capital Healthcare Fund, L.P. purchased 300,000 shares of common stock at $16.00 per share and 2,200,000 Pre-Funded Warrants at $15.9999 per warrant in Bicara Therapeutics' public offering.
• The total investment in the February 2026 Offering amounted to $39,999,780, funded by the Fund's working capital.
• The Pre-Funded Warrants include a "Beneficial Ownership Blocker" preventing exercise if it would result in ownership exceeding 9.99% of common stock outstanding, and the Reporting Persons are currently prohibited from exercising them.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant investment by a reputable healthcare fund like RA Capital indicates confidence in Bicara Therapeutics, despite the beneficial ownership blocker on warrants.

Positives

• A significant investment of nearly $40 million by a prominent healthcare-focused investment firm, RA Capital, signals confidence in Bicara Therapeutics.
• The acquisition of additional common stock and pre-funded warrants increases RA Capital's stake, potentially aligning their interests more closely with other shareholders.

Negatives

• The "Beneficial Ownership Blocker" on the Pre-Funded Warrants limits RA Capital's immediate ability to fully convert these warrants into common stock, capping their direct voting power from these specific instruments.

Risks

• The "Beneficial Ownership Blocker" provision in the Pre-Funded Warrants restricts the immediate exercise of 2,200,000 warrants if it would cause the Fund's ownership to exceed 9.99% of the common stock outstanding.
• Reporting Persons are currently prohibited from exercising the Pre-Funded Warrants, which could limit their flexibility in increasing their stake or influencing corporate actions through direct share ownership.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from Bicara Therapeutics Inc. It primarily reports an updated ownership stake by RA Capital Management and its affiliates.

Industry Context

StockSavvy.ai notes that a significant investment by a specialized healthcare fund like RA Capital Management in a biotechnology company such as Bicara Therapeutics often signals a vote of confidence in the company's pipeline, technology, or market potential. Such investments can attract further investor interest, particularly in the competitive and capital-intensive biotech sector where funding is crucial for R&D and clinical trials.

Stakeholder Impact

• Shareholders: Increased institutional ownership by RA Capital may be viewed positively, potentially signaling confidence and stability. The public offering itself would have diluted existing shareholders, but the participation of a major investor could offset some concerns.
• Company (Bicara Therapeutics): The capital raise from the public offering, including RA Capital's significant investment, provides additional funding for operations, research, and development.

Key Dates

Recommendation

The filing indicates a significant vote of confidence from a major institutional investor, RA Capital, through a substantial investment in Bicara Therapeutics' public offering. This increased stake to 11.5% suggests a positive long-term view. However, the presence of a beneficial ownership blocker on the pre-funded warrants, which currently prevents their exercise, introduces a degree of uncertainty regarding RA Capital's immediate ability to fully leverage its potential ownership. While the investment is a positive signal, the operational implications for Bicara Therapeutics are not detailed in this ownership filing, warranting a 'hold' recommendation until further operational or financial updates are available.

Keywords

Bicara Therapeutics, RA Capital Management, Schedule 13D/A, Common Stock, Pre-Funded Warrants, Public Offering, Institutional Investment, Biotechnology, Healthcare Fund, Beneficial Ownership